ACVR2B

ACVR2B is a type II serine/threonine kinase receptor of the TGF-β superfamily that binds activins, myostatin, BMP3, and select BMPs to transduce SMAD2/3 and SMAD1/5/8 signaling across diverse developmental and homeostatic contexts. ACVR2B forms ligand-enhanced homomeric complexes and assembles with type I receptors including ALK2 and ACVR1B; its constitutive homodimerization enables ligand-independent activation of the FOP-causing ALK2-R206H mutant, linking receptor oligomerization directly to disease pathogenesis (PMID:38334613). In skeletal muscle, ACVR2B mediates myostatin and activin signaling to negatively regulate muscle mass via SMAD2/3, and ligand trapping with soluble ACVR2B-Fc prevents muscle atrophy by restoring protein synthesis (PMID:27666826, PMID:22911153). ACVR2B also functions as the primary type II receptor for BMP-driven dorsoventral patterning, is required with ACVR2A for activin-dependent FSH production in gonadotropes, participates in BMP3-mediated suppression of osteoblast differentiation, and harbors mutations associated with left–right axis malformations in humans (PMID:32270195, PMID:22074949, PMID:9916847).

1. 1999 Medium

   The first human genetic link between ACVR2B and disease was established when mutations in ACVR2B were identified in patients with left–right axis malformations, consistent with prior mouse knockout data showing laterality defects.

   Evidence Mutation screening of 126 human laterality cases versus 200 controls, corroborated by mouse targeted disruption studies

   PMID:9916847

   Open questions at the time

   • Functional validation of specific human variants was not performed
   • Downstream pathway mediating left–right patterning via ACVR2B was not resolved
   • No structural basis for variant pathogenicity
2. 2011 High

   BMP3 was identified as a ligand that acts through ACVR2B to suppress osteoblast differentiation, establishing ACVR2B as a negative regulator of bone formation.

   Evidence Acvr2b siRNA knockdown in primary bone marrow stromal cells combined with BMP3 gain- and loss-of-function

   PMID:22074949

   Open questions at the time

   • Type I receptor partner for BMP3–ACVR2B signaling in osteoblasts was not identified
   • SMAD branch (SMAD2/3 vs SMAD1/5/8) downstream of BMP3–ACVR2B was not resolved
3. 2012 Medium

   The extracellular domain of ACVR2B was shown to directly inhibit myostatin activity, confirming its ligand-binding specificity and establishing the biochemical basis for soluble decoy receptor strategies.

   Evidence Recombinant ACVR2B-ECD expressed in Pichia pastoris tested in CAGA-luciferase reporter assay against myostatin in A204 cells

   PMID:22911153

   Open questions at the time

   • Fish ortholog ECD used; affinity constants for mammalian ACVR2B not determined
   • Competition with other TGF-β family ligands not systematically tested
4. 2015 High

   Activin A was shown to competitively antagonize BMP signaling specifically through ACVR2A/ACVR2B–ALK2 complexes but not BMPR2–ALK3/ALK6, revealing that ligand competition at the type II receptor determines BMP versus activin pathway output.

   Evidence Ligand competition in myeloma cell lines with defined BMP-receptor expression profiles

   PMID:26047946

   Open questions at the time

   • Structural basis for selective activin A displacement of BMPs from ACVR2B–ALK2 was not resolved
   • Physiological tissue contexts where this competition operates were not identified
5. 2016 Medium

   Blocking ACVR2B ligand signaling in vivo with soluble ACVR2B-Fc prevented chemotherapy-induced muscle atrophy by restoring protein synthesis rather than suppressing degradation, clarifying the anabolic arm of the receptor's muscle regulation.

   Evidence Mouse doxorubicin model with ACVR2B-Fc treatment; muscle protein synthesis measurement and atrogene profiling

   PMID:27666826

   Open questions at the time

   • Specific ligand(s) responsible for doxorubicin-induced signaling through ACVR2B were not identified
   • Downstream translational targets restoring synthesis were not characterized
6. 2019 High

   A ternary complex of ACVR2B–ACVR1B–NOX4 was identified in osteoarthritic cartilage, showing that NOX4 binds the receptor complex to amplify pathogenic SMAD2/3 signaling, expanding the receptor's known effector repertoire beyond SMADs.

   Evidence Co-immunoprecipitation, genetic mouse models (Col2a1-Inhba Tg, Nox4 KO), ACVR2B knockdown, and pSMAD2/3 readouts

   PMID:36950748

   Open questions at the time

   • Stoichiometry and structural interface of NOX4 binding to ACVR2B–ACVR1B not determined
   • Whether NOX4 association occurs with other type II receptor complexes was not tested
7. 2019 Medium

   Systemic ACVR2B ligand blockade was shown to protect against myocardial ischemia-reperfusion injury by antagonizing SMAD2 signaling, extending ACVR2B's role beyond skeletal muscle to cardiac stress responses.

   Evidence Mouse IR injury model with ACVR2B-Fc; in vitro cardiomyocyte hypoxia; echocardiography and mitochondrial respiration

   PMID:30765322

   Open questions at the time

   • Specific cardiomyocyte-expressed ligand driving pathogenic SMAD2 activation not identified
   • Single lab finding; independent replication not available
8. 2020 High

   Conditional knockout in gonadotropes demonstrated that ACVR2A and ACVR2B are jointly required for activin-dependent FSH production, with combined loss causing profound FSH deficiency and sterility.

   Evidence Cre-lox conditional knockout of Acvr2a/Acvr2b in murine gonadotropes; serum FSH, fertility phenotyping

   PMID:32270195

   Open questions at the time

   • Relative individual contributions of ACVR2A versus ACVR2B to FSH regulation in single KOs were partially redundant and not fully disentangled
   • Downstream transcriptional program linking receptor signaling to FSHβ gene expression not fully characterized
9. 2024 High

   Biophysical studies revealed that ACVR2B, unlike ACVR2A, forms stable homomeric complexes constitutively and can activate the FOP-causing ALK2-R206H mutant in a ligand-independent manner, providing a mechanistic explanation for differential receptor contributions to aberrant signaling in FOP.

   Evidence FRAP-based receptor immobilization/diffusion measurements; pSMAD1/5/8 and BRE-Luc reporter in cells expressing wild-type or R206H ALK2

   PMID:38334613

   Open questions at the time

   • Structural basis for constitutive ACVR2B homodimerization versus ACVR2A's ligand dependence not resolved
   • Whether ligand-independent activation of ALK2-R206H by ACVR2B occurs in patient tissues not demonstrated

• Key unresolved questions include the structural determinants of ACVR2B's constitutive oligomerization, the full repertoire of ACVR2B type I receptor pairings in specific tissues, and how competition among activins, myostatin, and BMPs for ACVR2B is spatiotemporally regulated in vivo.
• No high-resolution structure of a full-length ACVR2B homomeric or heteromeric signaling complex
• Tissue-specific type I receptor partnerships remain largely inferred from expression data
• Quantitative in vivo ligand competition dynamics at ACVR2B are uncharacterized